MedTrace Logo

Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients

NCT01111422 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2010-04-27

No results posted yet for this study

Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of reactive oxygen species may be responsible for progressive membrane dysfunction. N-acetylcysteine (NAC)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model. In this study the researchers investigated the hypothesis that NAC protect peritoneal membrane damage.

Conditions

  • End-Stage Kidney Disease
  • Peritoneal Dialysis

Interventions

DRUG

N-acetylcysteine

N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months

Sponsors & Collaborators

  • Ewha Womans University

    lead OTHER

Principal Investigators

  • Duk-Hee Kang, MD. PhD. · Ewha Womans University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-12-31
Completion
2011-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01111422 on ClinicalTrials.gov